599 related articles for article (PubMed ID: 15979412)
21. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
Hurtado JC; Kim SH; Pollok KE; Lee ZH; Kwon BS
J Immunol; 1995 Oct; 155(7):3360-7. PubMed ID: 7561030
[TBL] [Abstract][Full Text] [Related]
22. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
Gramaglia I; Weinberg AD; Lemon M; Croft M
J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
[TBL] [Abstract][Full Text] [Related]
23. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
24. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.
Gilham DE; O'Neil A; Hughes C; Guest RD; Kirillova N; Lehane M; Hawkins RE
J Immunother; 2002; 25(2):139-51. PubMed ID: 12074044
[TBL] [Abstract][Full Text] [Related]
25. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis.
Ren-Heidenreich L; Mordini R; Hayman GT; Siebenlist R; LeFever A
Cancer Immunol Immunother; 2002 Oct; 51(8):417-23. PubMed ID: 12202902
[TBL] [Abstract][Full Text] [Related]
27. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
Cheung NK; Guo HF; Modak S; Cheung IY
Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
[TBL] [Abstract][Full Text] [Related]
28. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
Maher J; Brentjens RJ; Gunset G; Rivière I; Sadelain M
Nat Biotechnol; 2002 Jan; 20(1):70-5. PubMed ID: 11753365
[TBL] [Abstract][Full Text] [Related]
29. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.
Dumitriu IE; Baruah P; Finlayson CJ; Loftus IM; Antunes RF; Lim P; Bunce N; Kaski JC
Circ Res; 2012 Mar; 110(6):857-69. PubMed ID: 22282196
[TBL] [Abstract][Full Text] [Related]
30. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
31. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
Ren-Heidenreich L; Hayman GT; Trevor KT
Hum Gene Ther; 2000 Jan; 11(1):9-19. PubMed ID: 10646635
[TBL] [Abstract][Full Text] [Related]
32. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
33. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.
Alvarez-Vallina L; Hawkins RE
Eur J Immunol; 1996 Oct; 26(10):2304-9. PubMed ID: 8898938
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Textor A; Listopad JJ; Wührmann LL; Perez C; Kruschinski A; Chmielewski M; Abken H; Blankenstein T; Charo J
Cancer Res; 2014 Dec; 74(23):6796-805. PubMed ID: 25297631
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
36. Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.
Zhang T; He X; Tsang TC; Harris DT
Cancer Gene Ther; 2004 Jul; 11(7):487-96. PubMed ID: 15153936
[TBL] [Abstract][Full Text] [Related]
37. Expression and functional significance of CTLA-4, a negative regulator of T cell activation.
Kosmaczewska A; Ciszak L; Boćko D; Frydecka I
Arch Immunol Ther Exp (Warsz); 2001; 49(1):39-46. PubMed ID: 11266089
[TBL] [Abstract][Full Text] [Related]
38. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
[TBL] [Abstract][Full Text] [Related]
39. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
40. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
Loskog A; Giandomenico V; Rossig C; Pule M; Dotti G; Brenner MK
Leukemia; 2006 Oct; 20(10):1819-28. PubMed ID: 16932339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
